Keywords: Biota, BARDA, Influenza antiviral, Funding, USA, Laninamivir

Biota awarded $231 million BARDA funding for development of new influenza antiviral

Article | 04 April 2011

Print This

A contract, worth $231 million over five years, has been awarded to Australian company Biota Holdings (ASX: BTA) to develop a ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in